Evidence map›Paper›PMID 27366097›Full record

ArticleOncoTargets and therapy2016

High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.

Xiao-Yi Chen, Guo-Qing Ru, Ying-Yu Ma, Jun Xie, Wan-Yuan Chen, Hui-Ju Wang, Shi-Bing Wang, Li Li, Ke-Tao Jin, Xiang-Lei He and 1 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiao-Yi ChenClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Guo-Qing RuDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Ying-Yu MaClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Jun XieDepartment of Anus-Intestines, Affiliated Hospital of Shaoxing University, Shaoxing, People's Republic of China.
Wan-Yuan ChenDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Hui-Ju WangClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Shi-Bing WangClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Li LiClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Ke-Tao JinDepartment of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, People's Republic of China.
Xiang-Lei HeDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Xiao-Zhou MouClinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
Zhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidemiologic evidence suggests that chronic inflammation and/or chronic infection is associated with cancer development, and the inflammatory process may play a crucial role in the carcinogenesis and prognosis of colorectal cancer (CRC). Substance P (SP) belongs to the family of tachykinins and acts as an immunomodulator, binding to the neurokinin-1 receptor (NK1R) to initiate tumor cell proliferation, angiogenesis, and migration, steps that are critical for tumor cell invasion and metastasis. It is suggested that SP/NK1R signaling may play an important role in cancer progression and metastasis. However, the exact involvement and significance of SP and NK1R in CRC pathologies remain to be adequately deciphered. PATIENTS AND

methodsWe performed immunohistochemistry staining on tissue microarrays containing 267 pairs of CRC and adjacent normal tissues to evaluate the clinical significance of SP or NK1R in the progression and prognosis of CRC. We also explored the potential correlation between SP and NK1R in CRC development.

resultsExpression levels of SP and NK1R were upregulated in CRC compared with their expressions in adjacent normal tissues (P<0.001). High expression of SP in CRC was significantly associated with lymph node metastasis (P<0.001). We also found that high expression of NK1R in CRC was significantly related to TNM (tumor node metastasis) stage (P=0.010) and lymph node metastasis (P=0.019). A high correlation between SP and NK1R expression was also observed (r=0.419, P<0.001). Survival analysis showed that CRC patients with high expression of SP or NK1R have a poor prognosis when compared to patients with low SP or NK1R expression (log rank test, P<0.05). Multivariate analysis using Cox regression model showed that survival was independently correlated with lymph node metastasis, distant metastasis, and SP expression (P<0.05).

conclusionUpregulation of SP-NK1R may play a crucial role in CRC progression. Moreover, SP-NK1R expression may also be used as a predictor for CRC prognosis.

Indexed as

CRCNK1RprognosisprogressionSP

Identifiers

PMID27366097
PMCPMC4913971
OpenAlexW2427441848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.